Department of Health and Human Services, through National Institutes of Health, awarded Allander Biotechnologies, Inc. of Aurora, CO $2,300,000 under the SBIR program (Phase II), with work starting 2025-09-15 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Allander Biotechnologies, Inc. received in the last two years, $3,510,798 in all. Each figure links to the federal record.
The award
| Recipient | Allander Biotechnologies, Inc. (Aurora, CO) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,300,000 |
| Period of performance starts | 2025-09-15 |
| Period of performance ends | 2027-08-31 |
| Award number | R44CA310522 (grant, CFDA 93.395) |
| Assistance listing | 93.395, Cancer Treatment Research |
| Place of performance | Aurora, Adams County, CO |
| Signed | 2025-09-08 |
| Recipient registry id (UEI) | J8KMX54WRJM9 |
Want the whole picture on Allander Biotechnologies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Allander Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Allander Biotechnologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients - summary oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy (rt o
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-14 | Continuation | 000 | $1,066,148 |
| 2025-09-08 | New | 000 | $1,233,852 |
First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients - summary oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy (rt or crt) and a limiting factor to using the optimal dose of radiation for effective cancer treatment. Intensity modulated rt (imrt) and stereotactic body rt (sbrt) spare more normal tissues and lessen chronic side effects, but not oral mucosa in head and neck cancer patients. Targeted therapies and immunotherapies make oral mucositis more prevalent than before. To date, palifermin, a protein derived from keratinocyte growth factor, is the only targeted therapy approved by the food and drug administration (FDA) for preventing oral mucositis in patients with hematopoietic malignancy followed by bone marrow transplant (4% of the at-risk population), but IT has no effect on existing mucositis. Allander biotechnologies has developed a proprietary biologic that shows prophylactic and therapeutic effects on radiation-induced oral mucositis in mice and dogs upon topical application to oral mucosa. We have 1) locked the process of the cgmp (certified good manufacturing practice) platform for manufacturing and release criteria; 2) established efficacy dose range and defined pharmacodynamics (pd) based on mechanisms of actions; 3) completed glp toxicology studies in ...
From the federal award record.
Other SBIR and STTR awards to Allander Biotechnologies, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-16 | Department of Health and Human Services | SBIR Phase II | $1,210,798 | Cgmp manufacturing the clinical batch of oral gel drug for treating oral mucositis in canc (record) |
Every other federal award to Allander Biotechnologies, Inc. on record
The federal register lists 4 other awards to the same registry id (UEI J8KMX54WRJM9), $7,161,982 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2023-09-21 | National Institutes of Health | $2,470,033 | Ind-enabling toxicology studies to reach ind approval for a proprietary biologic to treat oral mucositis in ca (SB1DE024659) |
| 2020-09-24 | National Institutes of Health | $1,680,879 | Proprietary drug to treat radiodermatitis (R44AR078669) |
| 2014-09-15 | National Institutes of Health | $1,500,000 | Topical proprietary biologic to treat oral mucositis (R44DE024659) |
| 2014-09-01 | National Institutes of Health | $1,511,070 | Proprietary biologic treatment to heal skin wounds (R44DE028718) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Allander Biotechnologies, Inc.Look up Allander Biotechnologies, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Allander Biotechnologies, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.